Steven M Schoenbart, OD | |
901 Stewart Ave, Suite 202, Garden City, NY 11530-4893 | |
(516) 794-0704 | |
(516) 794-7562 |
Full Name | Steven M Schoenbart |
---|---|
Gender | Male |
Speciality | Optometry |
Experience | 38 Years |
Location | 901 Stewart Ave, Garden City, New York |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1316914468 | NPI | - | NPPES |
A400005494 | Other | NY | PTAN |
C32791 | Other | NY | MEDICARE ID |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | VUT004712 (New York) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Schoenbart Vision Care-optometry,p.c. | 0345302865 | 2 |
News Archive
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding.
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.
A lack of safety at school is one of the correlates of childhood obesity, say researchers at the University of Montreal and its affiliated Research Centre at CHU Sainte Justine children's hospital.
New research published in the February 2015 issue of The FASEB Journal details a test developed using mice that can help measure two important aspects of retinal health-the function of retinal blood vessels and light-detecting cells. This approach opens new possibilities for understanding the molecular changes that occur in retinal disease and for evaluating the benefits of treatment early in the course of disease.
In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer.
› Verified 6 days ago
Provider Name | Schoenbart Vision Care-optometry,p.c. |
---|---|
Provider Type | Part B Supplier - Clinic/group Practice |
Provider Identifiers | NPI Number: 1467605337 PECOS PAC ID: 0345302865 Enrollment ID: O20081217000543 |
News Archive
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding.
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.
A lack of safety at school is one of the correlates of childhood obesity, say researchers at the University of Montreal and its affiliated Research Centre at CHU Sainte Justine children's hospital.
New research published in the February 2015 issue of The FASEB Journal details a test developed using mice that can help measure two important aspects of retinal health-the function of retinal blood vessels and light-detecting cells. This approach opens new possibilities for understanding the molecular changes that occur in retinal disease and for evaluating the benefits of treatment early in the course of disease.
In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer.
› Verified 6 days ago
Mailing Address | Practice Location Address |
---|---|
Steven M Schoenbart, OD 901 Stewart Ave, Suite 202, Garden City, NY 11530-4893 Ph: (516) 794-0704 | Steven M Schoenbart, OD 901 Stewart Ave, Suite 202, Garden City, NY 11530-4893 Ph: (516) 794-0704 |
News Archive
The U.S. Food and Drug Administration today approved Adynovate, Antihemophilic Factor (Recombinant), PEGylated for use in adults and adolescents, aged 12 years and older, who have Hemophilia A. Adynovate is modified to last longer in the blood and potentially require less frequent injections than unmodified Antihemophilic Factor when used to reduce the frequency of bleeding.
AmpliPhi Biosciences Corporation, a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the company has received positive feedback, via written response, from the U.S. Food and Drug Administration regarding its development plans for AB-PA01, without the need for a Type B Pre-IND meeting.
A lack of safety at school is one of the correlates of childhood obesity, say researchers at the University of Montreal and its affiliated Research Centre at CHU Sainte Justine children's hospital.
New research published in the February 2015 issue of The FASEB Journal details a test developed using mice that can help measure two important aspects of retinal health-the function of retinal blood vessels and light-detecting cells. This approach opens new possibilities for understanding the molecular changes that occur in retinal disease and for evaluating the benefits of treatment early in the course of disease.
In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer.
› Verified 6 days ago
America's Vision, L.l.c. Optometrist Medicare: Medicare Enrolled Practice Location: 743 Franklin Ave, Garden City, NY 11530 Phone: 516-746-2360 Fax: 516-294-1937 | |
200 West Optics, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 928 Old Country Rd, Garden City, NY 11530 Phone: 516-394-0001 Fax: 516-394-0003 | |
Dr. Chester S Fichandler, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 743 Franklin Ave, Garden City, NY 11530 Phone: 516-746-2360 Fax: 516-294-1937 | |
Long Island Vision Optometry Pc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 630 Old Country Rd Unit 493a, Garden City, NY 11530 Phone: 516-408-5330 Fax: 516-877-8105 | |
Davis Vision Optometrist Medicare: Medicare Enrolled Practice Location: 600 Old Country Rd, Garden City, NY 11530 Phone: 516-745-6565 Fax: 516-683-1729 | |
L'grand Optical Optometrist Medicare: Not Enrolled in Medicare Practice Location: 630 Old Country Rd, 493/a, Garden City, NY 11530 Phone: 516-741-0700 Fax: 516-741-0707 | |
Focus Medical Ny, Pllc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 743 Franklin Ave, Garden City, NY 11530 Phone: 516-741-6334 |